A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients
Latest Information Update: 14 May 2025
At a glance
- Drugs STC 314 (Primary)
- Indications Sepsis
- Focus Therapeutic Use
- Acronyms Sepsis
- Sponsors Grand Medical Pty Ltd.
Most Recent Events
- 07 May 2025 Primary endpoint (Changes in sequential organ failure (SOFA) scores from baseline on day 7 value) has been met.
- 07 May 2025 Results presented in the Grand Pharma Media Release
- 14 Aug 2024 New trial record